Vitasora Health (VHL) Investor Update summary

Strategic and operational progress

• Patient pipeline expanded to 250,000, with 50,000 patient TAM and up to 1,000 contacted and 350 onboarded weekly; 29 contracted clients and major ACO/payor contracts covering over 1 million lives.

• U.S. market entry in 2022 led to rapid operational control, expansion into skilled nursing facilities in Hawaii, and new agreements with legacy and major healthcare providers.

• Strategic partnerships and acquisitions, such as Access Managed Services and Ceras Healthcare, expand service offerings and cross-sell opportunities.

• Current priorities include achieving monthly profitability, enrolling 7,500 patients at $70 pppm, and advancing 15 contract discussions, including capitated models.

• Focus on operational efficiency, rationalizing legacy clients, and building a U.S.-based team to support growth.

Regulatory and reimbursement environment

• Recent AMA recommendations reduce RPM data requirements and patient engagement time, potentially doubling per patient per month revenue from $70–$90 to $140–$180 starting January 2026, pending CMS ratification.

• Regulatory support for remote patient monitoring is strong, with RPM recognized as a critical part of healthcare investment.

Financial and operational performance

• Recurring revenue is at AUD 6 million, with $211,000 banked in September and 71% quarter-on-quarter growth in patient program enrolments.

• Clinic in Cloud is forecasted to account for 20% of fee-for-service business by year-end, offering higher margins and streamlined client onboarding.

• Revenue models include fee-for-service (US$70–100 pppm), Clinic in Cloud (US$130–190 pppm), and risk-share (US$10–40 pmpm plus cost savings share).

• Risk-sharing model leverages AI-driven analytics to reduce hospitalisations and share in client cost savings.

• Current ARR is US$3.8m/A$5.7m, with annualised revenue of AU$1.5m from recent patient enrolment growth.